WARREN, N.J. — November 24, 2025 — Leads & Copy — Aquestive Therapeutics, Inc. (NASDAQ:AQST) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York City from December 2-4, 2025. According to the press release, the Aquestive team will be holding a fireside chat with Piper Sandler Sr. Research Analyst David Amsellem on December 4, 2025, at 10:00 a.m. ET.
The discussion will focus on Anaphylm™ (dibutepinephrine) sublingual film, including regulatory progress and commercial readiness. Management will also be hosting investor meetings on the same day.
A webcast of the fireside chat will be available under the “Events and Presentations” page of the Investors section of the company’s website. A replay of the webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients’ lives through innovative science and delivery technologies. The company is developing orally administered and topical gel products to deliver complex molecules, providing alternatives to standard therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world and is the exclusive manufacturer of these licensed products.
Aquestive also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, like PharmFilm®, and has drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various dermatology conditions.
Brian Korb of astr partners is listed as the investor contact, and can be reached at brian.korb@astrpartners.com.
Source: Aquestive Therapeutics, Inc.
